Zymeworks Inc. (ZYME) NASDAQ
24.11
-0.43(-1.75%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
24.11
-0.43(-1.75%)
Currency In USD
Address
114 East 4th Avenue
Middletown, BC V5T 1G4
Canada
Phone
16046781388
Website
Sector
Healthcare
Industry
Biotechnology
Employees
299
First IPO Date
April 28, 2017
| Name | Title | Pay | Year Born |
| Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President | 1.71M | 1962 |
| Paul Moore | Chief Scientific Officer | 998,368 | 1968 |
| Lindsey Foulkes | SVP of Corporate Development & Strategy | 0 | N/A |
| Paul R. Schneider | Executive VP & General Counsel | 0 | 1971 |
| Laura O'Connor | Senior VP & Chief Human Resources Officer | 0 | N/A |
| Shrinal Inamdar | VP of Investor Relations | 0 | N/A |
| Sabeen Mekan | SVP & Chief Medical Officer | 0 | 1980 |
| Mark Hollywood | Executive VP & Chief Operating Officer | 0 | 1969 |
| Scott Platshon | Executive VP & Chief Business Officer | 0 | 1991 |
| Diana Papove | Vice President of Corporate Communications | 0 | N/A |
| Kristin Stafford | Executive VP & CFO | 0 | 1983 |
| Bijal Desai | Senior Vice President of Finance | 0 | N/A |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.